Despite advances in antimicrobial treatments, infection remains a common complication of intensive chemotherapy in patients with acute leukemia. It has become progressively apparent that the current antimicrobial focus has shortcomings that result from disruption of the commensal microbial communities of the gut. These effects, collectively known as dysbiosis, have been increasingly associated worldwide with growing complications such as Clostridioides difficile infection, systemic infections, and antibiotic resistance. A revision of the current practice is overdue. Several innovative concepts have been proposed and tested in animal models and humans, with the overarching goal of preventing damage to the microbiota and facilitating its recovery. In this review, we discuss these approaches, examine critical knowledge gaps, and explore how they may be filled in future research.
Bibliographical noteFunding Information:
This work was supported by the following research grants to Armin Rashidi: A University of Minnesota Medical School Innovation award, a Marrow on the Move award from the Division of Hematology, Oncology, and Transplantation at the University of Minnesota, and an American Cancer Society Institutional Research Grant (ACS-IRG). Both authors receive research funding from Incyte Corp. We thank Michael Franklin (University of Minnesota) for his critical review of the manuscript.
© 2020 Elsevier Inc.
- Acute leukemia
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't